Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board
2018年2月20日 - 7:30PM
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutics that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on establishing the
first FDA-approved treatment for lactose intolerance, today
announced the appointment of William Chey, M.D., to its Medical
Advisory Board.
“We are pleased to have the guidance and support
from one of the leading and most respected experts in the field of
gastroenterology,” said Andrew J. Ritter, co-founder and president
of Ritter Pharmaceuticals, Inc. “Dr. Chey has provided us a great
deal of input into our Phase 3 protocol design of RP-G28 for the
treatment of lactose intolerance and we appreciate his continued
involvement as we prepare to begin enrollment into our Phase 3
trial in early summer.”
Dr. Chey is Nostrant Collegiate Professor of Gastroenterology
& Nutrition Sciences, Director of the GI Physiology Laboratory,
and Co-Director of the Michigan Bowel Control Program at Michigan
Medicine. He also serves as a member of the Board of Trustees of
the American College of Gastroenterology, the Board of Directors of
the Rome Foundation and a member of the Advisory Board of the
International Foundation of Functional GI Disorders. Dr. Chey has
authored more than 300 manuscripts, reviews and book chapters, and
he was the Co-Editor-in-Chief of the American Journal of
Gastroenterology from 2010 to 2015. He has been elected to “Best
Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr.
Chey has been inducted into the Clinical Excellence Society of the
Department of Medicine, received the Dean’s Outstanding Clinician
Award, was inducted into the League of Research Excellence at the
University of Michigan and has received the Distinguished Clinician
Award from the American Gastroenterological Association.
“I look forward to working with Ritter Pharmaceuticals as the
Company prepares to launch its first pivotal Phase 3 clinical trial
of RP-G28 for lactose intolerance,” commented Dr. Chey. “Lactose
intolerance affects approximately 40 million people in the U.S.
with limited treatment options available. I believe an FDA-approved
treatment for patients could greatly impact these patients’
lives.”
Ritter Pharmaceuticals’ Medical Advisory Board
also includes the following esteemed gastroenterology and lactose
intolerance experts:
- Dennis Savaiano, Ph.D., a Professor of Foods & Nutrition
and Former Dean at Purdue University;
- William J. Sanborn, M.D., Chief of the Division of
Gastroenterology and Director at the University of California San
Diego;
- W. Allan Walker, M.D., the Director of the Division of
Nutrition at Harvard Medical School;
- Byron L. Cryer, M.D., Professor of Internal Medicine, Digestive
and Liver Diseases, and Associate Dean at Southwestern Medical
School, University of Texas Southwestern;
- Todd Klaenhammer, Ph.D., Distinguished Professor of Food
Microbiology, Genetics, Genomics at North Carolina State
University.
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. The Company’s lead product, RP-G28, has the potential to
become the first FDA-approved treatment for lactose intolerance, a
condition that affects millions worldwide. RP-G28 has been studied
in Phase 2 trials and is now in Phase 3 clinical development. The
Company is further exploring the functionality and discovering the
therapeutic potential gut microbiome changes may have on
treating/preventing a variety of conditions including:
gastrointestinal diseases, immuno-oncology, metabolic, and liver
disease.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements refer to
future plans and expectations, including statements regarding the
timing of our first Phase 3 pivotal clinical trial. Management
believes that these forward-looking statements are reasonable as
and when made. However, such statements involve a number of
known and unknown risks and uncertainties that could cause the
Company’s future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Factors
that could affect the Company’s actual results are included in the
Company’s SEC filings, including the Company’s most recent reports
on Form 10-K and 10-Q filed with the SEC. These forward-looking
statements are made only as of the date hereof, and, except as
required by law, the Company undertakes no obligation to update or
revise its forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts Investor Contact:Jeffrey Benjamin
310-203-1000 jeffrey@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024